Do analysts recommend THAR or CEPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, THAR or CEPO?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Cantor Equity Partners N/A N/A -$6.66M -$0.29 N/A

Is THAR or CEPO more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Cantor Equity Partners N/A N/A -0.74%

Do analysts recommend THAR or MAAS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Maase 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, THAR or MAAS?

Tharimmune has higher earnings, but lower revenue than Maase. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Maase $109.05M 1.73 -$27.36M N/A N/A

Is THAR or MAAS more profitable?

Maase's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Maase N/A N/A N/A

Do analysts prefer TROO or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TROOPS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, TROO or THAR?

Tharimmune has lower revenue, but higher earnings than TROOPS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TROOPS $17.10M 11.93 -$27.91M N/A N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is TROO or THAR more profitable?

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets TROOPS N/A N/A N/A Tharimmune N/A -588.45% -264.41%

Do analysts rate THAR or TONX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verb Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate THAR or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, THAR or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A

Is THAR or CNTN more profitable?

Hillstream Biopharma's return on equity of -20.06% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Hillstream Biopharma N/A -20.06% -15.90%

Tharimmune (THAR) Competitors

$2.11 0.00 (0.00%)

As of 10/12/2026

Compare

THAR vs. CEPO, MAAS, TROO, TONX, and CNTN

Should you buy Tharimmune stock or one of its competitors? Tharimmune's main competitors and comparable companies include Cantor Equity Partners (CEPO), Maase (MAAS), TROOPS (TROO), Verb Technology (TONX), and Hillstream Biopharma (CNTN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Tharimmune compare to Cantor Equity Partners?

Tharimmune (NASDAQ:THAR) and Cantor Equity Partners (NASDAQ:CEPO) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.29	N/A

In the previous week, Cantor Equity Partners had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Cantor Equity Partners and 0 mentions for Tharimmune. Cantor Equity Partners' average media sentiment score of 0.83 beat Tharimmune's score of 0.00 indicating that Cantor Equity Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Cantor Equity Partners	Positive

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cantor Equity Partners' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Cantor Equity Partners	N/A	N/A	-0.74%

Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Cantor Equity Partners has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Summary

Cantor Equity Partners beats Tharimmune on 6 of the 9 factors compared between the two stocks.

How does Tharimmune compare to Maase?

Tharimmune (NASDAQ:THAR) and Maase (NASDAQ:MAAS) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Maase	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has higher earnings, but lower revenue than Maase.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Maase	$109.05M	1.73	-$27.36M	N/A	N/A

In the previous week, Maase had 4 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for Maase and 0 mentions for Tharimmune. Maase's average media sentiment score of 0.51 beat Tharimmune's score of 0.00 indicating that Maase is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Maase	Positive

1.2% of Tharimmune shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 87.6% of Maase shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Maase has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market.

Maase's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Maase	N/A	N/A	N/A

Summary

Maase beats Tharimmune on 6 of the 9 factors compared between the two stocks.

How does Tharimmune compare to TROOPS?

TROOPS (NASDAQ:TROO) and Tharimmune (NASDAQ:THAR) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

TROOPS's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TROOPS	N/A	N/A	N/A
Tharimmune	N/A	-588.45%	-264.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TROOPS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has lower revenue, but higher earnings than TROOPS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TROOPS	$17.10M	11.93	-$27.91M	N/A	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

1.2% of Tharimmune shares are owned by institutional investors. 1.1% of TROOPS shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TROOPS has a beta of 3.51, indicating that its share price is 251% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

In the previous week, TROOPS had 18 more articles in the media than Tharimmune. MarketBeat recorded 18 mentions for TROOPS and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat TROOPS's score of -0.46 indicating that Tharimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
TROOPS	Neutral
Tharimmune	Neutral

Summary

TROOPS beats Tharimmune on 5 of the 9 factors compared between the two stocks.

How does Tharimmune compare to Verb Technology?

Tharimmune (NASDAQ:THAR) and Verb Technology (NASDAQ:TONX) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Tharimmune has higher earnings, but lower revenue than Verb Technology. Verb Technology is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Verb Technology	$12.78M	13.19	-$148.48M	-$1.04	N/A

In the previous week, Verb Technology had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Verb Technology and 0 mentions for Tharimmune. Verb Technology's average media sentiment score of 1.79 beat Tharimmune's score of 0.00 indicating that Verb Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Verb Technology	Very Positive

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Verb Technology has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verb Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 7.2% of Verb Technology shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 21.4% of Verb Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tharimmune has a net margin of 0.00% compared to Verb Technology's net margin of -497.15%. Verb Technology's return on equity of -60.82% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Verb Technology	-497.15%	-60.82%	-59.56%

Summary

Verb Technology beats Tharimmune on 8 of the 11 factors compared between the two stocks.

How does Tharimmune compare to Hillstream Biopharma?

Tharimmune (NASDAQ:THAR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Hillstream Biopharma had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Hillstream Biopharma and 0 mentions for Tharimmune. Hillstream Biopharma's average media sentiment score of 1.28 beat Tharimmune's score of 0.00 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Hillstream Biopharma	Positive

Hillstream Biopharma's return on equity of -20.06% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Hillstream Biopharma	N/A	-20.06%	-15.90%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Summary

Hillstream Biopharma beats Tharimmune on 7 of the 9 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$79.61M	$27.89B	$13.51B	$13.21B
Dividend Yield	N/A	6.95%	6.08%	22.89%
P/E Ratio	-0.53	14.64	23.01	19.81
Price / Sales	N/A	333.54	489.14	81.34
Price / Cash	N/A	233.06	44.19	53.04
Price / Book	3.10	3.27	2.70	6.03
Net Income	-$12.20M	$1.11B	$1.32B	$380.34M
7 Day Performance	-9.83%	-0.82%	-0.17%	-2.34%
1 Month Performance	N/A	-0.52%	-2.57%	-5.31%
1 Year Performance	-32.37%	-0.10%	10.16%	-2.94%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	N/A	$2.11 flat	N/A	-27.7%	$79.61M	N/A	N/A	2	Gap Up
CEPO Cantor Equity Partners	N/A	$10.77 0.0%	N/A	+2.4%	$274.51M	N/A	N/A	2
MAAS Maase	0.42 of 5 stars	$12.29 -0.9%	N/A	+287.9%	$195.66M	$109.05M	N/A	731	News Coverage Short Interest Increase
TROO TROOPS	0.0976 of 5 stars	$1.58 -2.2%	N/A	+12.1%	$192.40M	$17.10M	N/A	47	Upcoming Earnings
TONX Verb Technology	1.5393 of 5 stars	$3.24 -7.7%	N/A	N/A	$178.43M	$12.78M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. CEPO, MAAS, TROO, TONX, and CNTN

How does Tharimmune compare to Cantor Equity Partners?

Summary

How does Tharimmune compare to Maase?

Summary

How does Tharimmune compare to TROOPS?

Summary

How does Tharimmune compare to Verb Technology?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. CEPO, MAAS, TROO, TONX, and CNTN

How does Tharimmune compare to Cantor Equity Partners?

Do analysts recommend THAR or CEPO?

Which has higher valuation and earnings, THAR or CEPO?

Does the media favor THAR or CEPO?

Do institutionals & insiders have more ownership in THAR or CEPO?

Is THAR or CEPO more profitable?

Which has more volatility and risk, THAR or CEPO?

Summary

How does Tharimmune compare to Maase?

Do analysts recommend THAR or MAAS?

Which has preferable earnings and valuation, THAR or MAAS?

Does the media favor THAR or MAAS?

Do insiders & institutionals believe in THAR or MAAS?

Which has more risk & volatility, THAR or MAAS?

Is THAR or MAAS more profitable?

Summary

How does Tharimmune compare to TROOPS?

Is TROO or THAR more profitable?

Do analysts prefer TROO or THAR?

Which has higher valuation and earnings, TROO or THAR?

Do institutionals and insiders have more ownership in TROO or THAR?

Which has more volatility & risk, TROO or THAR?

Does the media refer more to TROO or THAR?

Summary

How does Tharimmune compare to Verb Technology?

Which has better earnings & valuation, THAR or TONX?

Does the media refer more to THAR or TONX?

Which has more risk & volatility, THAR or TONX?

Do analysts rate THAR or TONX?

Do insiders and institutionals hold more shares of THAR or TONX?

Is THAR or TONX more profitable?

Summary

How does Tharimmune compare to Hillstream Biopharma?

Do insiders & institutionals have more ownership in THAR or CNTN?

Does the media prefer THAR or CNTN?

Is THAR or CNTN more profitable?

Which has better earnings & valuation, THAR or CNTN?

Do analysts rate THAR or CNTN?

Which has more volatility & risk, THAR or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools